CD27 and breast carcinoma: The fourth generation of FRα-targeted CAR-T cells containing the costimulatory domains CD28, 4-1BB, and CD27 demonstrated superior therapeutic efficacy in breast cancer due to the o combined benefits of the three costimulatory domains (32).